Teva has made a big push into the biosimilars market through a joint venture with Lonza, which will give the generics giant expertise in biologics manufacture.
A Chinese citizen has been fined more than $1.2m and sentenced to over six years in a US prison for distributing counterfeit drugs that appeared “identical to authentic pharmaceuticals”.
Sanofi-Aventis is to sell its liquid drug manufacturing plant in Colomiers, southwest France, to industry specialist Unither for an as yet undisclosed sum.
Non-profit R&D organisation Battelle is investing $200m in its facilities in Ohio, which will see the company’s contract research capabilities upgraded.
Senator Richard Moore has criticised transparency laws in Massachusetts, US, which he claims allow pharmaceutical companies to hide payments made to physicians conducting clinical trials.
in-PharmaTechnologist is joined by Aurore Domange, Pharmapack Manager, who details the highlights of this year’s show, which starts in Paris, France, this week.
BIOTECanada has warned the Canadian government that unless it supports biotechs 50 per cent could run out of money this year, resulting in thousands of people being made redundant.
Indian contract research firm Jubilant Biosys has teamed up with US company BioLeap to offer drug early-stage discovery services which incorporate computational drug design.
Drug contract services specialist inVentive Health has selected a new office in Somerset, New Jersey, US which will house its patient outcomes, clinical, health and commercial division.
US contract manufacturer Ash Stevens Inc has upgraded its active pharmaceutical ingredient (API) facility in Riverview, Michigan, with new equipment for parallel synthesis and calorimetry.
In the latest part of its “beyond our borders” scheme, the US FDA is asking drugmakers to volunteer supply chain information for drugs and APIs sourced outside the USA.
The market for packaging machinery is set to grow 5 per cent a year and be worth $40bn (€30.3bn) by 2012, driven partly by a hike in demand for drug products in “pharmerging” economies, according to a new industry report.
US biotechnology company Cel-Sci is hoping to offer contract manufacturing to pharmaceutical partners from its new facility in Baltimore, as it tries to raise money to support the clinical development of its cancer immunotherapy Multikine.
BayBio has called on California’s leaders to enact legislation to promote biomanufacturing in response to the aggressive policies pursued by other states.
Süd-Chemie Performance Packaging has expanded its range of bentonite desiccants, which it claims are cheaper and less environmentally damaging than silica gel alternatives.
The rise in international, multi-centre clinical trials has complicated reporting pathways and led to institutional review boards (IRBs) being overloaded with adverse events, according to FDA guidance.
Despite criticism in certain quarters, joint GMP inspections represent the best use of resources in an increasingly globalised market, according to the EMEA.
A FDA warning letter has been sent to a clinical investigator who administered incorrect doses of investigational drugs having taken the patient’s weight and height from their driving license.
A US HHS report on FDA oversight during trials has found that, with current procedures, the agency cannot tell whether drugmakers are disclosing complete financial information from all investigators who worked on a particular study.
Cincinatti, US-based clinical research organization Kendle has cut back its revenue expectations for 2008, primarily as a result of the strengthening of the US dollar, in common with some of its peers in the CRO sector.
There is still no formal offer on the table for Canadian contract manufacturer Patheon from JLL Patheon Holdings, an investment group which currently owns around 29 per cent of the firm.
Wyeth Pharmaceuticals is continuing efforts to improve its capabilities in the formulation and delivery of RNA through a strategic partnership with Santaris Pharma.
US drugmaker Adventrx Pharmaceuticals is reducing its workforce to just 14 employees in a bid to preserve cash and refocus efforts on bioequivalence programmes for its lead candidates.
Sanofi-Aventis Canada has licensed I-many’s suite of software for managing pharmaceutical contracts, with the IT company also performing installation, maintenance and support.
December's packaging deal between McKesson and Burgopak is further evidence of drug industry's determination to improve patient compliance. in-PharmaTechnologist asked Burgopak's global head of automation Mark Symonds for further details...
An open house at GSK’s plant in Pennsylvania, US gave the world its first glimpse of the facility that the firm hopes will become the global hub of its vaccine packaging and filling business.
Akrimax Pharmaceuticals, which entered the contract manufacturing sector via the purchase of a Wyeth facility in New York, US, a year ago - has signed its first third-party agreement.
Since its inauguration last year, IPEC China has been working to improve the quality of excipient manufacturing in the country. in-PharmaTechnologist spoke with organisation president Nevin Cheng about the steps the body has taken so far and what it will...
A $1bn fraud scandal has rocked Indian IT outsourcing company Satyam, which provides services to leading pharmaceutical companies, and resulted in three of its executives spending the weekend in jail.
Finnish drugmaker Orion is to follow through on plans to cut its R&D workforce and shed 205 employees to sure up operations as generic pressure mounts on its leading Parkinson’s disease drugs.
Drug raw materials maker Akron Biotechnology has selected Austin Chemical Company to help expand its client-base in the global biotech, pharmaceutical, and diagnostic industries.
Contract research organisation Bio-Imaging Technologies has decided to sell off its CapMed subsidiary in order to focus its efforts on its core business, providing imaging series to clinical investigators.
The proportion of global clinical trials conducted In India is expected to more than double between 2007 and 2012, according to market research firm RNCOS.
The FDA has established its first permanent presence in Latin America by opening an office in Costa Rica as part of “Beyond Our Borders Initiative”, which has also seen the agency set up three sites in China.
Abbott Laboratories has licensed Liquidia Technologies’ PRINT nanoparticle technology for the delivery of siRNA-based therapeutics, which have the potential to improve the company’s cancer portfolio.
US-based BioReliance has won the contract to supply bulk adenovirus for several live oral vaccines being produced by Barr Pharmaceutical’s Duramed subsidiary.
India’s health authorities may invest RPS5bn ($102m) to re-open three state run vaccine manufacturing firms in a bid to combat current shortages, according to reports in the country’s media.
Halo Pharmaceuticals hopes that its acquisition of Abbott Laboratories’ 200,000 sq ft formulation, manufacturing and warehousing facility in Whippany, New Jersey will help it blossom into a CMO and development organisation.
Clinical laboratory services company LabCorp saw its shares slide yesterday after cutting back its sales and earnings targets for 2009 in light of the economic downturn.
Merck & Co’s thirst for outsourcing continues, with United Parcel Services (UPS) taking over two of its distribution centres and providing services from for the pharma company from the sites.
Nitec has received approval in Europe for its rheumatoid arthritis treatment Lodotra making it the first product using SkyePharma’s propriety drug delivery technology Geoclock to come to market.
In the future it may be possible to grow supplies of blood platelets in bioreactors rather than relying on donated supplies, according to US researchers.
Contract research organization Pharmaceutical Product Development Inc (PPD) has moved further into providing central laboratory services with the purchase of a 130,000 sq. ft. laboratory from Merck & Co.
As 2008 drew to a close and people the world over welcomed the New Year, few would have noticed the passing of Europe’s paracetamol industry as Rhodia closed the doors of the region’s last manufacturing facility in Roussillon, southern France.
